Dipeptide derivatives of AZT: Synthesis, chemical stability, activation in human plasma, hPEPT1 affinity, and antiviral activity by Cledir Santos et al.
DOI: 10.1002/cmdc.200800012
Dipeptide Derivatives of AZT: Synthesis, Chemical
Stability, Activation in Human Plasma, hPEPT1 Affinity, and
Antiviral Activity
Cledir Santos,[b] Jos Morais,[a] Lus Gouveia,[a] Erik de Clercq,[c] Christophe Pannecouque,[c]
Carsten Uhd Nielsen,[d] Bente Steffansen,[d] Rui Moreira,*[a] and Paula Gomes*[b]
Introduction
The human immunodeficiency virus (HIV), the etiological agent
of acquired immunodeficiency syndrome (AIDS), is one of the
most important global health problems. In 2007, the estimated
number of people living infected with the virus worldwide was
33.2 million.[1] AZT (3’-azido-3’-deoxythymidine, zidovudine,
Retrovir ; 1, Figure 1) was the first 2’,3’-dideoxynucleoside (ddN)
approved by the US Food and Drug Administration (FDA) for
the treatment of patients suffering from AIDS.[1–5] The mecha-
nism of action of AZT involves its conversion into the corre-
sponding 5’-O-triphosphate, which inhibits the replication of
the virus by competitive inhibition of the viral reverse tran-
scriptase (RT) and by incorporation and subsequent chain ter-
mination of the growing viral DNA strand.[6] Despite the devel-
opment of additional RT inhibitors and agents that block other
crucial steps in viral infection and replication, AZT is still the
most used anti-HIV agent. However, administration of AZT is
frequently associated with a significant dose-dependent toxici-
ty, particularly destruction of bone marrow cells, myopathy,
and hepatic abnormalities.[7] In addition, the short half-life
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5’-O-Dipeptide ester prodrugs of antiviral zidovudine (AZT) were
designed to target the human intestinal oligopeptide transporter,
hPEPT1, and were evaluated for their stability at pH 7.4 in buffer
and in human plasma, affinity toward hPEPT1, cytotoxicity, and
antiretroviral activity. The dipeptide esters of AZT undergo cycliza-
tion in buffer at pH 7.4 to release the parent drug at a rate that
depends on the size of the side chains of the peptide carrier ; the
prodrug is considerably more stable if bulky b-branched amino
acids such as Ile and Val are present, particularly as C-terminal
residues. Incubation in human plasma showed that most of the
dipeptide esters of AZT release the parent drug through two ami-
nopeptidase-mediated pathways: 1) stepwise cleavage of each of
the amino acids and 2) direct cleavage of the dipeptide–drug
ester bond. However, the plasma hydrolysis of Gly-Gly-AZT and
Phe-Gly-AZT showed only direct cleavage of the dipeptide–drug
ester bond. Substrate half-lives in plasma were again remarkably
high when hydrophobic b-branched amino acids (Val, Ile) were
present. The esters were also good substrates for the intestinal
oligopeptide transporter hPEPT1 in vitro, with Val-Gly-AZT and
Val-Ala-AZT presenting the highest affinity toward the transporter
(IC50 : 0.20 and 0.15 mm, respectively). The AZT dipeptide esters
were assayed against the IIIB and ROD strains of HIV, and their
cytotoxicity was evaluated in MT-4 cells. The selectivity index of
the prodrugs was two- to threefold higher than that of AZT for
all compounds analyzed. These results point to the potential of
dipeptide-based carriers for the development of effective antiviral
drug-delivery systems. Val-Ala-AZT appears to combine chemical
stability with good affinity for the hPEPT1 transporter and an im-
proved cytotoxicity/antiretroviral index relative to AZT.
Figure 1. Structure of AZT (1) and its dipeptide prodrugs 2.
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(~1 h) of AZT in human plasma requires frequent administra-
tion to maintain therapeutic drug concentrations. Moreover,
only 35 to 70% of the AZT plasma concentration is found in
the cerebrospinal fluid (CSF) even at high doses.[8] The entry of
AZT into brain tissue from the CSF is not sufficient to effective-
ly suppress viral replication in the brain, thus limiting its clinical
usefulness.[9]
The prodrug strategy has been widely used in attempts to
deliver AZT intracellularly, to improve anti-HIV efficacy, to de-
crease bone marrow toxicity, to increase plasma half-life and
lipophilicity, and to improve delivery to the brain.[10–23] For ex-
ample, l-amino acid-5’-O-AZT ester prodrugs, designed to en-
hance the absorption of the parent drug via an amino acid
transport system,[13,24, 25] were reported to display less cytotox-
icity than AZT. These esters of AZT were susceptible to the
action of plasma esterases with half-lives of 20-70 min, except
for the 5’-O-isoleucinyl derivative which did not undergo enzy-
matic hydrolysis for up to 4 h,[13] suggesting that the slow re-
lease of AZT from prodrugs may be related to the observed
decrease in toxicity. When studying the mechanism of absorp-
tion of the 5’-O-valyl ester of AZT using the rat perfusion
model, Amidon and co-workers found that the intestine was
threefold more permeable to the prodrug than to AZT. Com-
petitive inhibition studies in rats and in Chinese hamster ovari-
an (CHO) cells transfected with the human H+/peptide co-
transporter, hPEPT1, showed that the membrane transport of
Val-AZT was mediated predominantly by hPEPT1, even though
this compound did not contain a peptide bond. The 50% in-
hibition concentration (IC50) value for Val-AZT was lower than
for cephradine and enalapril, which are substrates for the pep-
tide transporter.[26] Val-AZT also exhibited threefold higher
uptake in Caco-2/hPEPT1 cells than AZT and similar studies
have demonstrated that the analogous l-valyl derivative of
acyclovir also displayed enhanced oral absorption due to its
specific recognition by the hPEPT1 transporter. These findings
were the basis for selecting 5’-amino acid esters of other anti-
viral nucleosides to target the intestinal hPEPT1 peptide trans-
porter as a strategy to improve oral bioavailability. More re-
cently, Mitra and co-workers developed dipeptide esters of acy-
clovir,[27,28] gancyclovir[29] and saquinavir[30,31] to improve the
ocular and intestinal bioavailability of these drugs. To the best
of our knowledge, dipeptide carriers have not been so far em-
ployed for AZT. In view of this, we set out to prepare and
study a family of eight dipeptide esters of AZT, 2 (Figure 1), as
substrates for the hPEPT1 transporter. Compounds 2 were de-
signed taking into account the known structural requirements
for molecular recognition by the peptide transporter, that is,
preference for 1) the natural l,l-dipeptide skeleton, 2) a free
amino group in the N-terminal, and 3) uncharged hydrophobic
side-chains. To obtain structure–reactivity information, Gly, Ala,
Phe, Val, and Ile residues covering a wide range of stereoelec-
tronic properties and lipophilicity were selected. We now
report the synthesis of dipeptide esters 2, their stability and
degradation pathways in pH 7.4 buffer and in human plasma,
in vitro activity against HIV-1 (IIIB) and HIV-2 (ROD) and in vitro
recognition by the hPEPT1 transporter.
Results and Discussion
Chemistry
The synthetic pathway to the AZT prodrugs is illustrated in
Scheme 1 and was based on stepwise introduction of the
amino acid residues. AZT was firstly reacted with the appropri-
ate Na-tert-butyloxycarbonyl-protected amino acid (BocAA1OH)
using O-(benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium tetra-
fluoroborate (TBTU) as coupling agent in the presence of N-
ethyl-N,N-diisopropylamine (DIEA). The corresponding Na-Boc-
protected amino acid esters 3a–e were isolated, Boc removed
with trifluoroacetic acid (TFA) and the resulting trifluoroace-
tates 4a–e were then reacted with the second Na-Boc-protect-
ed amino acid (BocAA2OH) to yield the protected dipeptide
esters 5a–h that were converted into the final products (com-
pounds 2a–h ; Figure 1) again with TFA.[32,33]
Chemical stability
The AZT esters 2a–h were incubated in pH 7.4 phosphate iso-
tonic buffer at 37 8C and reaction progress was monitored by
high-performance liquid chromatography (HPLC) and the
pseudo-first-order rate constants, kobs, thus determined are pre-
sented in Table 1. HPLC quantitative analysis of degradation
products showed that AZT was released with concomitant for-
mation of diketopiperazines (DKPs) and is consistent with the
expected intramolecular acyl transfer reaction (compare with
Scheme 2) that has been reported as the major degradation
pathway for simple dipeptide alkyl and aryl esters.[34–36] Com-
pounds 2a–h decompose to AZT in pH 7.4 buffer with half-
Scheme 1. Synthesis of AZT 5’-O-dipeptide esters 2a–h : a) BocAA1OH or Bo-
cAA2OH (1 equiv), TBTU (1 equiv), DIEA (2 or 3 equiv), CH2Cl2, 0 8C (2 h) !
room temperature (70 h); b) TFA (40% in CH2Cl2), room temperature, 30 min.
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lives ranging from 30 min to 115 h (Table 1). Stability of dipep-
tide esters 2 is dependent on the pH, increasing significantly
as pH decreases (data not shown). For example, Val-Val-AZT,
2 f, showed no measurable degradation after incubation for
five days in pH 4.0 buffer at 37 8C.
The rate of AZT release from 2 depends on the size of the
side chains of the peptide carrier, the prodrug being considera-
bly more stable when bulky b-branched amino acids (i.e. Ile
and Val) are present as C-terminal residues. For example, the
order of half-lives for the Gly-AA1-AZT series is Gly-Gly, 2a<
Gly-Phe, 2c!Gly-Val, 2b, with 2b being ~35-fold less reactive
than 2a. Similarly, for the Val-AA1-AZT series, Val-Gly, 2d<Val-
Ala, 2e!Val-Val, 2 f<Val-Ile, 2g, with 2 f being ~30-fold less
reactive than 2d. The effect of a b-branched amino acid in the
N-terminus of the dipeptide carrier on reactivity is smaller: for
example, Gly-Val-AZT, 2b, is only fivefold more reactive than
Val-Val-AZT, 2 f. Interestingly, the same difference in reactivity
was observed between the Gly-Val and Val-Val dipeptide esters
of acyclovir and saquinavir at pH 7.4 and 7.2, respectively.
Overall, these results suggest that steric hindrance at the C-ter-
minus of the dipeptide backbone is the major factor affecting
the rate of cyclization.[37]
Hydrolysis in human plasma
Dipeptide esters 2 were incubated at 37 8C in 80% human
plasma and their degradation monitored by HPLC. The degra-
dation of the esters displayed first-order kinetics for three to
four substrate half-lives. Detailed quantitative analysis revealed
that compounds 2b–g hydrolyze with formation of the corre-
sponding amino acid esters 4 as reaction intermediates, while
2a and 2h release directly the parent drug in the conditions
used. In all cases, formation of AZT was quantitative. These re-
sults suggest that the pathway for enzymatic degradation of
esters 2 to the parent drug occurs via 1) stepwise removal of
the amino acid residues and 2) direct cleavage of the dipeptide
carrier (Scheme 3), depending on the amino acid sequence. An
example of product analysis is presented in Figure 2 for the
hydrolysis of Val-Ala-AZT, 2e, where the solid lines represent
the best computer fit to the experimental data of a model rep-
resented by Equations (1)–(3). Additional examples of time pro-
Table 1. Kinetic data for the hydrolysis of compounds 2 in phosphate buffer (pH 7.4) and in human plasma at 37 8C.
Compound R1 R2 Buffer Human plasma
104kobs [s
1] 104kobs [s
1][a] 104k1,2 [s
1] 104k1,3 [s
1] 104k2,3 [s
1]
2a, Gly-Gly-AZT H H 3.91 23.0[b] 0 23.0 –
2b, Gly-Val-AZT iPr H 0.110 2.51 1.37 0.837 0.619
2c, Gly-Phe-AZT CH2Ph H 2.02 27.5 8.30 20.9 5.12
2d, Val-Gly-AZT H iPr 0.578 4.62 0.367 4.58 6.98
2e, Val-Ala-AZT Me iPr 0.561 7.29 3.07 5.62 9.76
2 f, Val-Val-AZT iPr iPr 0.0207 1.48 0.989 0.223 0.740
2g, Val-Ile-AZT sBu iPr 0.0167 1.12 0.847 0.349 0.358
2h, Phe-Gly-AZT H CH2Ph 1.28 7.90
[b] 0 7.90 –
[a] Pseudo-first-order rate constants for the disappearance of dipeptide substrates 2. [b] Direct release of AZT (no intermediate aminoacyl-AZT derivatives
4 detected).
Scheme 2. AZT release through intramolecular cyclization of a dipeptide
prodrug 2 in aqueous buffers.
Scheme 3. Pathways observed for AZT release from dipeptide esters 2 in
human plasma.
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files for the decomposition of compounds 2 in human plasma
are supplied as Supporting Information.
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In Equations (1)–(3), C1 stands for concentration of the di-
peptide ester substrate 2, C2 is the concentration of the inter-
mediate amino acid ester 4 and C3 is the concentration of AZT,
k1,2 is the first-order rate constant for the loss of the terminal
amino acid, k1,3 is the first-order rate constant for the loss of
the dipeptide carrier and k2,3 is the first-order rate constant for
the hydrolysis of the amino acid intermediate 4. The k1,2, k1,3
and k2,3 values derived from the time-courses for substrates
2b–g and their hydrolysis products are presented in Table 1.
Further support for the degradation pathway depicted in
Scheme 3 comes from the good agreement between the cal-
culated, k2,3, and the experimentally determined first-order rate
constants, kobs, for the plasma-catalyzed hydrolysis of amino
acid ester intermediates 4a–e (4a, Gly-AZT, 6.85M104 s1; 4b,
Ala-AZT, 8.99M104 s1; 4c, Val-AZT, 6.25M105 s1; 4d, Ile-AZT,
3.24M105 s1; 4e, Phe-AZT, 5.10M104 s1). Moreover, the kobs
values for compounds 4b–g are also in good agreement with
the sum of k1,2 and k1,3 values calculated from fitting Equa-
tions (1)–(3) to the experimental data. In contrast to 2b–g, sub-
strates 2a and 2h released the parent drug exclusively
through direct cleavage of the dipeptide carrier, that is, with
k1,2=0. As shown in Table 1, these were also the two sub-
strates that most rapidly degraded to yield free AZT. Interest-
ingly, direct release of Gly-Gly has also been reported for the
hydrolysis of the Gly-Gly benzyl ester in 80% human plasma.[35]
The high reactivity shown by 2a (t1/2~5 min) correlates with
experimental observations made in the course of the hPEPT1
affinity assays (see the following section).
The experimental observations for the degradation of 2 in
human plasma are consistent with substrate enzymatic hydrol-
ysis promoted by plasmatic amino- and diaminopeptidases, in
agreement with previous findings by Jensen et al.[35] and Ma-
jumdar et al.[38] while studying di-/tripeptide esters of benzyl al-
cohol and the Val-Val ester of acyclovir, respectively. Dipeptide
esters 2 are ~6 to 70-fold more susceptible to plasma hydroly-
sis than to chemical degradation in pH 7.4 buffer. Nevertheless,
AZT release from 2 in human plasma is still very slow for sub-
strates possessing two bulky b-branched amino acids, such as
2 f (Val-Val-AZT) and 2g (Val-Ile-AZT). It is noteworthy that
amino acid hydrophobicity is not enough to assure slow re-
lease of AZT, as the phenylalanine dipeptide (2c, 2h) and
amino acid (2e) esters of AZT were clearly less stable than
their Val and Ile counterparts (Table 1). This is reinforced by
previous findings from Yang et al. who described the phenyla-
lanine ester of acyclovir (the counterpart of 4e) to be highly
susceptible to plasma enzymes, with an in vitro half-life of
1.3 min.[39] Thus, amino acid b-branching seems to be a key
factor to induce slow release of the parent drug.
Affinity of compounds 2 for hPEPT1 in Caco-2 cell
monolayers
The affinity of dipeptide esters 2 for hPEPT1 was determined
by displacement studies of [14C]glycylsarcosine ([14C]GlySar) in
filter-grown Caco-2 cell monolayers, as described in the Experi-
mental Section. Substrate stability under conditions employed
in the uptake assays investigated by HPLC-UV showed that all
compounds 2 were stable, with the exception of the glycylgly-
cine derivative 2a. The inhibition data for 2a–h are presented
as IC50 values in Table 2. All compounds presented IC50,hPEPT1
values under 10 mm, which is below the value reported for
cephradine in CHO/hPEPT1 cells (152 mm),[26] except 2a,
which showed very weak affinity for hPEPT1, and 2b, with a
IC50,hPEPT1 value of 16.8 mm.
Figure 2. Time profile for the decomposition of 2e (*) into 4b (&) and AZT
(~) in 80% human plasma at pH 7.4 and 37 8C; solid lines represent the best
fit of experimental data to the reaction model depicted in Scheme 3.
Table 2. In vitro affinities of compounds 2a–h for the intestinal oligopep-
tide transporter hPEPT1 in Caco-2 cell monolayers.
Compound logP[a] IC50,hPEPT1 [mm]
[b]
2a 0.36 >1000
2b 0.34 16.80.9
2c 1.04 7.21
2d 0.28 0.200.01
2e 0.63 0.150.01
2 f 1.17 6.01
2g 1.58 8.80.8
2h 1.05 9.00.7
[a] Obtained using ALOGPS 2.1 (available at VCCLAB, Virtual Computa-
tional Chemistry Laboratory: http://www.vcclab.org). [b] Concentration re-
quired to decrease apical uptake of [14C]Gly-Sar by 50%.
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Inspection of Table 2 shows that compounds having valine
as N-terminal amino acid generally displayed the highest affini-
ties for hPEPT1 (i.e. Val-Gly-AZT, 2d, Val-Ala-AZT, 2e and Val-
Val-AZT, 2 f), whereas the lowest affinities were observed for
substrates having glycine as the N-terminal amino acid (i.e.
Gly-Gly-AZT, 2a and Gly-Val-AZT, 2b). These results suggest
that valine as the N-terminal residue of the dipeptide carrier is
a major structural requirement for molecular recognition of
compounds 2 by hPEPT1 and are consistent with those ob-
tained for dipeptide and amino acid derivatives of other antivi-
ral agents and with the hypothesis that valine might represent
the optimal combination of chain length and b-branching for
intestinal absorption.[40] For example, Jain et al. found that the
Val-Val ester of saquinavir (Val-Val-SQV) exhibits higher absorp-
tion rate constant and intestinal permeability in rat jejunum
than its Gly-Val counterpart.[31] The affinity of Val-Val-SQV
toward peptide transporters expressed in MDCKII-MDR1 cells is
also higher than that of Gly-Val-SQV.[30] In the present study,
Val-Val-AZT 2 f also exhibited good affinity for the peptide
transporter, being ranked third within the series studied. Simi-
larly, Amidon and co-workers reported a clearly higher affinity
of Val-acyclovir toward hPEPT1 relative to that of Gly-acyclovir
under identical conditions.[26]
The lack of a clear correlation between log (1/IC50,hPEPT1) and
logP presented in Figure 3, suggests that binding of prodrugs
2 to the peptide transporter does not require lipophilic dipep-
tidic carriers. This result contrasts with that obtained for amino
acid prodrugs of the antiviral agent 2-bromo-5,6-dichloro-1-(b-
d-ribofuranosyl)benzimidazole that showed a marked increase
in the affinity of the prodrug for hPEPT1 transporter with the
lipophilicity of the amino acid derivative.[41] However, if the
sub-set Gly-AA-AZT, 2a–c, is analyzed, then the order of Gly-
Sar uptake inhibition by AA is Phe>Val@Gly. This is consistent
with the order of lipophilicity of AA (pBz=2.6; piPr=1.3; pH=
0.0) and indicates that contribution of dipeptide lipophilicity to
the binding properties of prodrugs 2 cannot be entirely ruled
out. A similar result was reported for the inhibition of Gly-AA
dipeptides on the Gly-Sar uptake by PEPT1 in human intestinal
Caco-2 cells.[42] This is further confirmed by the observation
that the affinities of compounds with identical logP values do
not differ significantly (e.g. Gly-Phe-AZT, 2c, and Phe-Gly-AZT,
2h ; Table 2). For the sub-set Val-AA-AZT, 2d–g, the order of
Gly-Sar uptake inhibition by AA is Ala>Gly>Val>Leu, which
suggests that steric hindrance exerted by AA might affect affin-
ity toward hPEPT1 when a b-branched amino acid is present at
the N-terminus of the dipeptide backbone.
Full saturation curves were obtained for two of the most in-
teresting Val-AA1-AZT derivatives, 2d and 2e, and are dis-
played in Figure 4. The curves do not show 100% inhibition of
[14C]Gly-Sar uptake, but this might be an artifact due to a resid-
ual amount of extracellular isotope, as previously reported.[43]
Both curves are almost superimposable, indicating that not
only are 2d and 2e very good substrates for hPEPT1, but also
their interactions with this transporter are remarkably similar.
Any possible artifact behind this similarity, due to eventual
substrate degradation in the course of uptake assays, has been
ruled out by the stability study. Overall, these assays demon-
strate that dipeptide esters 2 are good substrates for the intes-
tinal hPEPT1 oligopeptide transporter, especially when valine is
used as the N-terminal amino acid.
In vitro anti-HIV and cytotoxic activity
Compounds 2a–h were also evaluated for inhibition of the cy-
topathic effects of HIV-1 (IIIB) and HIV-2 (ROD) viral strains in
MT-4 cells, and the results are presented in Table 3. Com-
pound-induced cytotoxicity was also measured in MT-4 cells in
parallel with the antiviral activity. As shown by the IC50,HIV
values presented in Table 3, all dipeptide esters 2a–h display
anti-HIV activity identical to that of AZT against both HIV-1 and
HIV-2.
More relevantly, the compounds showed 50% cytotoxic con-
centration (CC50) values that were two- to fourfold higher than
that of AZT, indicating that the AZT dipeptide esters are clearly
less cytotoxic than the parent drug. Again, the Val-Ile-AZT (2g)
derivative is the most promising compound, as it is the least
cytotoxic of the series. Neither the antiviral activities nor cyto-
toxicities of prodrugs 2 correlated with the logP values, sug-
Figure 3. Plot of log (1/IC50,hPEPT1) versus logP for AZT dipeptide esters 2b–h.
The logP values were obtained using ALOGPS 2.1, available at VCCLAB, Vir-
tual Computational Chemistry Laboratory: http://www.vcclab.org.
Figure 4. Full saturation curves for compounds 2d (*) and 2e (&) for
hPEPT1-mediated apical Gly-Sar uptake in Caco-2 cell monolayers. Lines rep-
resent the best fit of experimental data to Equation (4).
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gesting that lipophilicity might not have a significant role in
their diffusion into the cells and/or in the intracellular delivery
of AZT.
Prodrugs 2a–h are more selective than AZT, as their cytotox-
icities (given by CC50 values) are generally lower than that of
the parent drug, while their anti-HIV activities (given by IC50,HIV
values) are identical to that of AZT. This can be easily illustrated
by a selectivity index (SI) associated to each compound 2a–h,
being SI=CC50/IC50,HIV (Table 3). Thus, the data in Table 3 show
that esters 2a–h are two- to threefold more selective than the
parent drug. An interesting observation is that the most selec-
tive AZT prodrugs contain a Val residue either at the N-termi-
nus (2d–g) or C-terminus (2b) of the peptide carrier. A similar
decrease in cytotoxicity for amino acid esters of AZT, as com-
pared with the parent drug, has been also described by Aggar-
wal et al.[13] One of the least cytotoxic esters of the set studied
by these authors was the Ile ester of AZT, which agrees with
the fact that the least cytotoxic ester from Table 3 is 2g, i.e. ,
the dipeptide ester that also contains Ile directly bound to
AZT. However, at present we cannot exclude the possibility
that the released amino acid and dipeptides may have some
effect on decreasing the toxicity of AZT.
Conclusions
5’-O-Dipeptide ester derivatives of AZT, 2, are quantitatively hy-
drolyzed to the parent drug in pH 7.4 buffer and in human
plasma. Prodrugs 2 bearing b-branched amino acids, such as
valine, at N-terminus of the dipeptide carrier exhibit high affini-
ties toward the intestinal oligopeptide transporter hPEPT1.
These compounds are suggested to be activated by plasma
amino- and diaminopeptidases to slowly and quantitatively re-
lease the parent anti-HIV drug, with the advantage of being
less cytotoxic than the parent drug. Overall, the results show
that, with correct tailoring of the dipeptide moiety, dipeptide
esters of AZT may represent a viable way to minimize some of
the problems associated with AZT-based therapies, such as low
oral bioavailability and toxicity. Such an approach would allow
the re-introduction of AZT, through suitable derivatives as pro-
drugs, as a reference agent for the treatment of AIDS.
Experimental Section
Materials. Boc-amino acids and TBTU were obtained from Bachem,
and solvents were all of p.a. quality from Merck and were dried
over pre-activated 3 P molecular sieves prior to use. All remaining
reactants were from Sigma–Aldrich. Silica gel 60 plates (Merck F254)
were used for thin-layer chromatography. NMR spectra were ac-
quired on a Bruker AMX 300 spectrometer from solutions of the
compounds in hexadeuterated dimethyl sulfoxide ([D6]DMSO)
having tetramethylsilane (TMS) as internal reference: 1H and 13C
chemical shifts are given in parts per million (ppm) and proton–
proton coupling constants in Hertz (Hz); 1H NMR peak multiplicity
is indicated by br s (broad singlet), s (singlet), d (doublet), dd
(double doublet), t (triplet), q (quartet), m (unresolved multiplet).
MS data were acquired by either the matrix-assisted laser desorp-
tion ionization time-of-flight (MALDI-ToF) or the electrospray ioni-
zation ion-trap (ESI-IT) techniques, on a Bruker Biflex II or a Finni-
gan LCQ DECA XP MAX spectrometer, respectively. Elemental anal-
yses (EA) were run on a LECO CHNS-932 instrument.
Synthesis of compounds 3a–e. The relevant BocAA1OH (1 equiv),
TBTU (1 equiv) and DIEA (2 equiv) were dissolved in CH2Cl2 at 0 8C
and the mixture stirred for 10 min prior to addition of AZT
(1 equiv). The mixture was stirred at 0 8C for further 2 h, then at
room temperature for a further 70 h. After washing the crude mix-
ture with 30% aqueous KHSO4 and 30% aqueous Na2CO3, the or-
ganic layer was dried over anhydrous MgSO4 and evaporated to
dryness yielding a brownish oil that was identified as the desired
product by NMR and MS (see Supporting Information).
Preparation of trifluoroacetates 4a–e. Each compound 3a–e was
dissolved in 40% TFA in CH2Cl2 and the reaction was allowed to
reach completion (~30 min) at room temperature. The target tri-
fluoroacetate was precipitated with diethyl ether and isolated after
centrifugation at 3300 rpm and 9 8C. Compounds 4a–e were iso-
lated as white hygroscopic solids (stored over anhydrous calcium
chloride on a vacuum desiccator) and their structures confirmed
by NMR and EA (see Supporting Information).
Synthesis of compounds 5a–h. Two solutions were prepared in
parallel in separate flasks at 0 8C, one containing each trifluoroace-
tate 4a–e (1 equiv) and DIEA (1 equiv) dissolved in CH2Cl2 and the
other containing the relevant BocAA2OH (1 equiv), TBTU (1 equiv)
and DIEA (2 equiv) also in CH2Cl2. After being stirred for 10 min,
both solutions were mixed together and subsequent procedures
were as described for compounds 3. Compounds 5 were isolated
pure, as brownish oils, and their identity confirmed by NMR and
MS (see Supporting Information).
Preparation of the target trifluoroacetates 2a–h. The final com-
pounds were obtained as white hygroscopic solids by acidolysis of
their Boc-protected precursors 5a–h, following the procedure de-
scribed above for the preparation of trifluoroacetates 4a–e. Their
structures were confirmed by NMR and EA, as described below.
Table 3. Anti-retroviral activity and cytotoxicity data for AZT and its deriv-
atives 2a–h.
Compd Strain IC50,HIV [nm]
[a] CC50 [mm]
[b] SI[c]
2a
HIV-2 ROD 2.9
15.0
5172
HIV-1 IIIB 1.8 8333
2b
HIV-2 ROD 4.0
20.0
5000
HIV-1 IIIB 1.9 10526
2c
HIV-2 ROD 3.0
14.1
4700
HIV-1 IIIB 1.5 9400
2d
HIV-2 ROD 2.8
15.6
5571
HIV-1 IIIB 1.6 9750
2e
HIV-2 ROD 3.2
19.6
6125
HIV-1 IIIB 1.8 10889
2 f
HIV-2 ROD 3.9
18.1
4641
HIV-1 IIIB 1.5 12067
2g
HIV-2 ROD 4.0
19.6
4900
HIV-1 IIIB 1.5 13067
2h
HIV-2 ROD 2.3
14.4
6261
HIV-1 IIIB 1.7 8471
AZT
HIV-2 ROD 3.7
8.46
2286
HIV-1 IIIB 1.9 4453
[a] 50% inhibitory concentration, or concentration required to inhibit the
viability of HIV-infected cells by 50% (average values from at least two in-
dependent assays). [b] 50% cytotoxic concentration, or concentration re-
quired to inhibit the viability of mock-infected cells by 50% (average
values from at least two independent assays). [c] SI=CC50/IC50,HIV.
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O-Glycylglycyl-3’-azido-2’,3’-dideoxythymine trifluoroacetic acid
salt, 2a. Yield, 25%; 1H NMR (300 MHz, [D6]DMSO, 25 8C, TMS): d=
1.80 (s, 3H, CH3); 2.34–2.48 (m, 2H, CH2); 3.63 (s, 2H, CH2); 3.99 (m,
3H, CHH+ CH2); 4.31 (m, 2H, CH+CH); 4.51 (m, 1H, CHH) ; 6.12 (t,
3J ACHTUNGTRENNUNG(H,H)=6.3 Hz, 1H, CH); 7.46 (s, 1H, =CH); 8.11 (br s, 3H, NH3
+) ;
8.87 (t, 3JACHTUNGTRENNUNG(H,H)=5.7 Hz, 1H, NH); 11.3 ppm (s, 1H, NH). 13C NMR
(75.4 MHz, [D6]DMSO, 25 8C, TMS): d=12.05 (CH3); 35.39 (CH2);
40.48 (CH2); 59.82 (CH); 63.87 (CH2); 80.40 (CH); 83.58 (CH); 109.92
(C=) ; 136.09 (=CH); 150.31 (CO); 163.60 (CO); 166.59 (CO);
169.20 ppm (CO). C16H20F3N7O8·2H2O (531.16 gmol
1): N, 18.46; C,
36.18; H, 4.55%; Found: N, 18.80; C, 36.33; H, 4.33%.
O-Glycylvalyl-3’-azido-2’,3’-dideoxythymine trifluoroacetic acid salt,
2b. Yield, 73%; 1H NMR (300 MHz, [D6]DMSO, 25 8C, TMS): d=0.90
(d, 3J ACHTUNGTRENNUNG(H,H)=6.9 Hz, 6H, 2MCH3); 1.81 (s, 3H, CH3); 2.11–2.35 (m, 2H,
CH2); 2.54 (m, 1H, CH); 3.66 (s, 2H, CH2); 4.00 (m, 1H, CHH); 4.32
(m, 3H, 3MCH); 4.51 (m, 1H, CHH) ; 6.12 (t, 3J ACHTUNGTRENNUNG(H,H)=6.6 Hz, 1H,
CH); 7.46 (s, 1H, =CH); 8.10 (br s, 3H, NH3
+) ; 8.71 (d, 3J ACHTUNGTRENNUNG(H,H)=
8.1 Hz, 1H, NH); 11.4 ppm (s, 1H, NH). 13C NMR (75.4 MHz,
[D6]DMSO, 25 8C, TMS): d=12.04 (CH3); 17.75 (CH3); 18.78 (CH3);
29.95 (CH); 35.32 (CH2); 57.38 (CH); 60.09 (CH); 64.04 (CH2); 80.32
(CH); 83.72 (CH); 109.89 (C=) ; 136.02 (=CH); 150.31 (CO); 163.59
(CO); 166.39 (CO); 170.83 ppm (CO). C19H26F3N7O8·H2O
(555.20 gmol1): N, 17.66; C, 41.10; H, 5.08%; Found: N, 17.21; C,
40.63; H, 4.95%.
O-Glycylphenylalanyl-3’-azido-2’,3’-dideoxythymine trifluoroacetic
acid salt, 2c. Yield, 93%; 1H NMR (300 MHz, [D6]DMSO, 25 8C, TMS):
d=1.80 (s, 3H, CH3); 2.34 (m, 2H, CH2); 2.98 (dd,
2J ACHTUNGTRENNUNG(H,H)=13.8 Hz,
3J ACHTUNGTRENNUNG(H,H)=8.4 Hz, 1H, CHH); 3.08 (dd, 2JACHTUNGTRENNUNG(H,H)=13.7 Hz, 3J ACHTUNGTRENNUNG(H,H)=
5.9 Hz, 1H, CHH) ; 3.58 (s, 2H, CH2); 3.96 (m, 1H, CHH) ; 4.26 (m, 3H,
3MCH); 4.61 (m, 1H, CHH) ; 6.11 (t, 3J ACHTUNGTRENNUNG(H,H)=6.6 Hz, 1H, NH); 7.24
(m, 5H, ArH); 7.44 (s, 1H, =CH); 8.07 (br s, 3H, NH3
+) ; 8.97 (d, 3J-
ACHTUNGTRENNUNG(H,H)=7.5 Hz, NH); 11.4 ppm (s, 1H, NH). 13C NMR (75.4 MHz,
[D6]DMSO, 25 8C, TMS): d=12.09 (CH3); 35.48 (CH2); 36.67 (CH2);
53.79 (CH); 59.85 (CH); 64.20 (CH2); 80.26 (CH); 83.60 (CH); 109.97
(C=) ; 126.74 (ArCH); 128.32 (ArCH); 129.04 (ArCH); 135.86 (ArC);
136.50 (=CH); 150.29 (CO); 163.60 (CO); 166.11 (CO); 170.75 ppm
(CO). C23H26F3N7O8·H2O (603.20 gmol
1): N, 16.25; C, 45.79; H,
4.70%; Found: N, 15.92; C, 45.34; H, 4.71%.
O-Valylglycyl-3’-azido-2’,3’-dideoxythymine trifluoroacetic acid salt,
2d. Yield, 73%; 1H NMR (300 MHz, [D6]DMSO, 25 8C, TMS): d=0.96
(m, 6H, 2MCH3); 1.80 (s, 3H, CH3); 2.09–2.35 (m, 2H, CH2); 2.48 (m,
1H, CH); 3.67 (d, 3JACHTUNGTRENNUNG(H,H)=5.1 Hz, 1H, CH); 3.98 (m, 2H, CH2); 4.06
(m, 1H, CHH); 4.32 (m, 2H, 2MCH); 4.48 (m, 1H, CHH) ; 6.14 (t, 3J-
ACHTUNGTRENNUNG(H,H)=6.6 Hz, 1H, CH); 7.48 (s, 1H, =CH); 8.17 (br s, 3H, NH3
+) ;
8.93 (m, 1H, NH); 11.4 ppm (s, 1H, NH). 13C NMR (75.4 MHz,
[D6]DMSO, 25 8C, TMS): d=12.03 (CH3); 17.54 (CH3); 17.99 (CH3);
29.74 (CH); 35.36 (CH2); 40.46 (CH2); 57.19 (CH); 59.91 (CH); 63.97
(CH2); 80.41 (CH); 83.59 (CH); 109.89 (=C); 136.09 (=CH); 150.31
(CO); 163.58 (CO); 168.42 (CO); 169.10 ppm (CO). C19H26F3N7O8·2
H2O (573.21 gmol
1): N, 17.10; C, 39.81; H, 5.27%; Found: N, 17.05;
C, 40.19; H, 5.02%.
O-Valylalanyl-3’-azido-2’,3’-dideoxythymine trifluoroacetic acid salt,
2e. Yield, 75%; 1H NMR (300 MHz, [D6]DMSO, 25 8C, TMS): d=0.95
(m, 6H, 2MCH3); 1.36 (d,
3J ACHTUNGTRENNUNG(H,H)=7.5 Hz, 3H, CH3); 1.80 (s, 3H,
CH3); 2.07–2.33 (m, 2H, CH2); 2.48 (m, 1H, CH); 3.61 (d,
3J ACHTUNGTRENNUNG(H,H)=
5.1 Hz, 1H, CH); 3.97 (m, 1H, CHH); 4.30 (m, 2H, 2MCH); 4.38 (m,
1H, CH); 4.45 (m, 1H, CHH) ; 6.10 (t, 3J ACHTUNGTRENNUNG(H,H)=6.6 Hz, 1H, CH); 7.47
(s, 1H, =CH); 8.14 (br s, 3H, NH3
+) ; 8.90 (d, 3J ACHTUNGTRENNUNG(H,H)=6.3 Hz, 1H,
NH); 11.4 ppm (s, 1H, NH). 13C NMR (75.4 MHz, [D6]DMSO, 25 8C,
TMS): d=12.00 (CH3); 16.65 (CH3); 17.47 (CH3); 18.04 (CH3); 29.72
(CH3); 35.28 (CH2); 47.65 (CH); 57.12 (CH); 60.05 (CH); 64.11 (CH2);
80.34 (CH); 83.60 (CH); 109.90 (=C); 136.03 (=CH); 150.30 (CO);
163.57 (CO); 167.72 (CO); 171.68 ppm (CO). C20H28F3N7O8·H2O
(569.22 gmol1): N, 17.22; C, 42.20; H, 5.31%; Found: N, 17.00; C,
41.90; H, 5.31%.
O-Valylvalyl-3’-azido-2’,3’-dideoxythymine trifluoroacetic acid salt,
2 f. Yield, 58%; 1H NMR (300 MHz, [D6]DMSO, 25 8C, TMS): d=0.94
(m, 12H, 4MCH3); 1.80 (s, 3H, CH3); 2.11–2.34 (m, 3H, CH+CH2);
2.48 (m, 1H, CH); 3.76 (m, 1H, CH); 3.98 (m, 1H, CHH); 4.29 (m, 3H,
3MCH); 4.47 (m, 1H, CHH) ; 6.12 (t, 3J ACHTUNGTRENNUNG(H,H)=6.6 Hz, 1H, CH); 7.48 (s,
1H, =CH); 8.14 (br s, 3H, NH3
+) ; 8.66 (d, 3J ACHTUNGTRENNUNG(H,H)=7.5 Hz, 1H, NH);
11.4 ppm (s, 1H, NH). 13C NMR (75.4 MHz, [D6]DMSO, 25 8C, TMS):
d=12.00 (CH3); 17.36 (CH3); 17.88 (CH3); 18.16 (CH3); 18.74 (CH3);
29.60 (CH); 29.84 (CH); 35.20 (CH2); 56.90 (CH); 57.65 (CH); 60.18
(CH); 64.11 (CH2); 80.33 (CH); 83.66 (CH); 109.86 (=C); 136.04
(=CH); 150.31 (CO); 163.57 (CO); 168.37 (CO); 170.59 ppm (CO).
C22H32F3N7O8·H2O (597.25 gmol
1): N, 16.42; C, 44.24; H, 5.74%;
Found: N, 16.21; C, 44.22; H, 5.87%.
O-Valylisoleucyl-3’-azido-2’,3’-dideoxythymine trifluoroacetic acid
salt, 2g. Yield, 38%; 1H NMR (300 MHz, [D6]DMSO, 25 8C, TMS): d=
0.88 (m, 12H, 4MCH3); 1.23 (m, 1H, CHH); 1.40 (m, 1H, CHH) ; 1.80
(s, 3H, CH3); 1.84 (m, 1H, CH); 2.08–2.34 (m, 2H, CH2); 2.48 (m, 1H,
CH); 3.72 (d, 3J ACHTUNGTRENNUNG(H,H)=5.1 Hz, CH); 3.98 (m, 1H, CHH); 4.30 (m, 3H,
3MCH); 4.45 (m, 1H, CHH) ; 6.12 (t, 3J ACHTUNGTRENNUNG(H,H)=6.6 Hz, CH); 7.47 (s, 1H,
=CH); 8.08 (br s, 3H, NH3
+) ; 8.62 ppm (m, 1H, NH); 11.4 (s, 1H,
NH). 13C NMR (75.4 MHz, [D6]DMSO, 25 8C, TMS): d=11.13 (CH3);
12.00 (CH3); 15.29 (CH3); 17.37 (CH3); 18.15 (CH3); 24.53 (CH2); 29.84
(CH); 35.13 (CH2); 36.10 (CH); 56.65 (CH); 56.93 (CH); 60.28 (CH);
64.20 (CH2); 80.33 (CH); 83.73 (CH); 109.84 (=C); 136.06 (=C);
150.31 (CO); 163.57 (CO); 168.32 (CO); 170.56 ppm (CO).
C23H34F3N7O8·2H2O (629.27 gmol
1): N, 15.58; C, 43.89; H, 6.08%;
Found: N, 15.43; C, 44.01; H, 5.93%.
O-Phenylalanylglycyl-3’-azido-2’,3’-dideoxythymine trifluoroacetic
acid salt, 2h. Yield, 73%; 1H NMR (300 MHz, [D6]DMSO, 25 8C, TMS):
d=1.80 (s, 3H, CH3); 2.36–2.48 (m, 2H, CH2); 2.96 (m, 1H, CHH);
3.13 (m, 1H, CHH) ; 4.00 (m, 3H, 3MCH); 4.09 (m, 1H, CHH); 4.32
(m, 2H, CH2); 4.52 (m, 1H, CHH) ; 6.13 (t,
3J ACHTUNGTRENNUNG(H,H)=6.6 Hz, 1H, CH);
7.29 (m, 5H, ArH); 7.47 (s, 1H, =CH); 8.19 (br s, 3H, NH3
+) ;
9.00 ppm (m, 1H, NH); 11.4 (s,1H, NH). 13C NMR (75.4 MHz,
[D6]DMSO, 25 8C, TMS): d=12.05 (CH3); 35.37 (CH2); 36.93 (CH2);
40.54 (CH2); 53.24 (CH); 59.84 (CH); 63.96 (CH2); 80.42 (CH); 83.61
(CH); 109.90 (=C); 127.10 (ArCH); 128.46 (ArCH); 129.46 (ArCH);
134.69 (ArC); 136.10 (=CH); 150.30 (CO); 163.59 (CO); 168.70 (CO);
169.05 ppm (CO). C23H26F3N7O8·1.5H2O (612.52 gmol
1): N, 16.00; C,
45.10; H, 4.27%; Found: N, 16.21; C, 44.22; H, 4.87%.
General procedure for the monitoring of AZT release by HPLC–
UV. A solution of the compound to be assayed (104m) in aqueous
buffer (pH 7.4) was kept at a constant temperature of 37.00.1 8C;
aliquots were periodically taken and immediately injected (loop of
100 mL) in the HPLC system, using a LichroCart 250–4 Lichrospher
100 RP-8 reversed-phase column (250M4 mm, 5 mm); the elution
was isocratic, at varying proportions of CH3CN in aqueous buffer
(sodium hexanesulfonate 10 mm, sodium acetate 2.5 mm, phos-
phoric acid 2.5 mm ; pH 6.3) and at a flow rate of 1.0 mLmin1,
with UV detection at 240 nm; AZT and the relevant diketopipera-
zines (DKPs) were used as standards for peak identification. The hy-
drolyses of prodrugs in human plasma were studied by the HPLC-
UV method described above. Plasma was obtained from hepari-
nized blood of healthy donors, pooled, and frozen at 70 8C
before use. The prodrugs were incubated at an initial concentra-
tion of 104m at 37 8C in human plasma diluted to 80% (v/v) with
pH 7.4 isotonic phosphate buffer. At appropriate intervals, 30 mL
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aliquots were added to 270 mL acetonitrile in order to quench the
reaction and to eliminate proteins from the plasma. These samples
were centrifuged for 5 min at 13000 rpm and the supernatant was
analyzed by HPLC for the presence of substrate, AZT, DKP and cor-
responding 5’-O-amino acid intermediate.
Affinity for hPEPT1 in Caco-2 cells
Materials. Caco-2 human colon carcinoma cells were obtained
from the ATCC (Rockville, MD, USA). Cell culture media and Hank’s
balanced salt solution (HBSS) were obtained from Life Technologies
(Høje TUstrup, Denmark). [14C]Gly-Sar with a specific activity of
49.90 mCimmol1 was purchased from New England Nuclear
(Boston, MA). 2-[N-Morpholino]ethanesulfonic acid (MES), 2-[4-(2-
hydroxyethyl)-1-piperazine]ethanesulfonic acid (HEPES), and glycyl-
sarcosine (Gly-Sar) were purchased from Sigma–Aldrich (St. Louis,
MO, USA). All analytical grade solvents used for HPLC analysis were
obtained from Merck (Darmstadt, Germany), and Ultima Gold scin-
tillation fluid was purchased from Packard (Groningen, The Nether-
lands). Transepithelial resistance (TEER) was measured in tissue re-
sistance measurement chambers (Endohm) with a voltohmmeter
from World Precision Instruments (Sarasota, FL, USA). The Swip KS
10 Digi shaking plate used for cell culture experiments was from
Edmund BVhler (Hechingen, Germany). Caco-2 cell monolayers
with a TEER higher than 200 Wcm2 were used for affinity studies.
Radioactivity was counted with a Tri-Carp 2110TR liquid scintillation
analyzer from Packard (Perkin–Elmer Life and Analytical Sciences,
Boston, MA).
Affinity assays. The affinities of compounds 2b–h were deter-
mined as IC50-values by studying the inhibition of apical [
14C]Gly-
Sar uptake into filter-grown 25 days old Caco-2 cell monolayers, as
described previously.[44] In short, the applied buffers were HBSS
supplemented with 0.05% bovine serum albumin (BSA) and
10 mm MES (pH 6.0) or 10 mm HEPES (pH 7.4). The cell monolayer
was initially incubated for 15 min at 37 8C with buffers at pH 6.0
and 7.4 applied apically and basolaterally, respectively. The inhibi-
tion study was then performed by apically incubating the mono-
layer for 5 min at 37 8C with a mixture of 0.5 mCi [14C]Gly-Sar and
10 mm compounds 2. After incubation, the cells were washed
three times with ice-cold HBSS, and the individual filters were re-
moved to count the cell-associated radioactivity by liquid scintilla-
tion analysis. Full saturation curves were measured for compounds
2c and 2d, through similar inhibition experiments where the con-
centration of 2c and 2d ranged from 0 to 2.5 mm. The IC50 were
estimated either from the full saturation curve or from the degree
of Gly-Sar inhibition observed at 10 mm compounds 2 using Mi-
chaelis–Menten-like kinetic analysis:
1 U
U0
¼

1

U
U0

max
½I	
IC50 þ ½I	
ð4Þ
where U is the apical uptake of Gly-Sar, U0 is the apical uptake of
Gly-Sar without inhibitor, [I] is the concentration of inhibitor, and
IC50 is the concentration of inhibitor required to decrease the
apical uptake of [14C]Gly-Sar by 50%. Measurements were carried
out in duplicate (N=2) using three individual Caco-2 cell passages
(n=3).
Stability in 80% human plasma
HPLC–UV analysis. High-performance liquid chromatography
(HPLC) measurements were carried out using a Waters assembly
equipped with a model 600 controlled pump and a model 991
photodiode-array detector. A Rheodyne 7725 injection valve
equipped with 20 mL sample loop was used. Acquisition and treat-
ment of data were made by means of NEC for MS-DOS, version
3.30 software. The separation was performed on a Purospher,
250M4.0 mm i.d. 5 mm (Merck, Germany) analytical column, with a
LiChrospher 100 RP-8 5 mm (Merck, Germany) pre-column. The sol-
vent system used was a mixture of 78% (v/v) sodium acetate
buffer (pH 6.30; 2.50 mm) (A) and 22% (v/v) acetonitrile (B) for iso-
cratic elution of compounds 2b and 2d–f. Elution of 2a was iso-
cratic at 18% B, whereas for compounds 2c and 2g–h a gradient
elution was carried out as follows: 0 min, 23% B; 5.0 min, 23% B;
6.0 min, 30% B; 11.0 min, 30%; 11.5 min, 23% B; 15.0 min, 23% B.
Solvent flow rate was 1 mL/min for isocratic elutions and
1.5 mLmin1 for gradient elutions. A 15 mLmin1 nitrogen sparge
was applied to remove dissolved gases. Chromatographic separa-
tion was monitored by UV detection at 265 nm. All analyses were
performed at room temperature.
Hydrolysis in human plasma. Compounds 2 were incubated at
37 8C in human plasma (from heparinized blood of healthy donors)
diluted to 80% (v/v) with pH 7.4 isotonic phosphate buffer. At ap-
propriate intervals, aliquots were added to acetonitrile to quench
the reaction and precipitate plasma proteins. These samples were
centrifuged and the supernatant was analyzed by the HPLC
method described above for the presence of substrate and prod-
ucts.
In vitro anti-HIV assays. The methodology of the anti-HIV assays
has been previously described.[45] Briefly, MT-4 cells were infected
with HIV-1 (IIIB) and HIV-2 (ROD) at 100-fold the CCID50 (50% cell
culture infective dose) value per mL cell suspension. Then, 100 mL
of the infected cell suspension were transferred to microtiter plate
wells, mixed with 100 mL of the appropriate dilutions of test com-
pounds, and further incubated at 37 8C. After 5 days of incubation
of MT-4 cells, the number of viable cells was determined by a tetra-
zolium-based colorimetric method. The 50% inhibition concentra-
tion (IC50) was defined as the concentration of compound required
to inhibit cell viability by 50% in MT-4 cells. The cytotoxic concen-
tration CC50 was determined as the concentration of compound re-
quired to inhibit by 50% the number of viable cells in mock-infect-
ed MT-4 cell cultures.
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